Business
ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine
ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine.
About this update from Protokinetix, Inc.
[{"type":"text","content":"\nProtoKinetix, Incorporated (www.protokinetix.com) (the \"Company\" or \"ProtoKinetix\") (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders.\n\n\n“Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage and improved viability when challenged with multiple stressors,” said esteemed biochemist and toxicologist, Dr. Thomas Pulinilkunnil. “This in vitro data supporting the therapeutic utility of PKX-001 is expected to augment the progress of the whole organ and animal studies while screening PKX-001 for inflammatory, hypertrophic and ischemic pathologies in cardiovascular medicine.”\n\n\nSee the promising research of AAGP® and results to date\n\n\nAbout ProtoKinetix, Incorporated \n\n\nProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP®) that enhance both engraftment and protection of transplanted cells, tissues and organs used in regenerative medicine. Due to the results achieved over the last four years of testing, the University of Alberta has begun Phase 1 human clinical trials. Additional studies will be expanded to include whole organ transplantation and all therapies that are being developed globally to date; diabetes, retinal degeneration, cardiac repair and many other degenerative conditions. In addition, we are studying the potential impact on several cancer therapies.\n\n\nCautionary Note Regarding Forward-Looking Statements\n\n\nThe information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified ...